KRBP — Kiromic Biopharma Share Price
0.000.00%
Last trade - 00:00- $2.82m
- $8.10m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kiromic BioPharma, Inc. is a clinical-stage fully integrated biotherapeutics company using its DIAMOND artificial intelligence (AI) 2.0 target discovery engine to develop and commercialize cell therapies focusing on immuno-oncology. The Company is developing multi-indication allogeneic T cell therapies that exploit the natural potency of Gamma Delta T cells (GDTs) to target solid tumors. It has three product candidates: Deltacel non-engineered GDTs, expanded and activated with technology, Procel GDTs engineered with a PD-1 switch receptor and Isocel GDTs engineered with an anti-Mesothelin isoform 2 Chimeric Antigen Receptor. Its Procel and Isocel product candidates consist of allogeneic, engineered, off-the-shelf GDT cells and they are in the preclinical development stage. Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. It also has new technologies in development to support its end-to-end approach.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- May 27th, 2016
- Public Since
- October 16th, 2020
- No. of Shareholders
- 83
- No. of Employees
- 31
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 1,288,235
- Address
- 7707 Fannin St., Suite 140, HOUSTON, 77054
- Web
- https://kiromic.com/
- Phone
- +1 8329684888
- Auditors
- Deloitte & Touche LLP
Upcoming Events for KRBP
Q3 2024 Kiromic Biopharma Inc Earnings Release
Similar to KRBP
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the Kiromic Biopharma share price?
As of Today at 21:39 UTC, shares in Kiromic Biopharma are trading at $2.51. This share price information is delayed by 15 minutes.
How has the Kiromic Biopharma share price performed this year?
Shares in Kiromic Biopharma last closed at $2.51 and the price had moved by -20.57% over the past 365 days. In terms of relative price strength the Kiromic Biopharma share price has underperformed the S&P500 Index by -33.34% over the past year.
What are the analyst and broker recommendations for Kiromic Biopharma?
There is no consensus recommendation for this security.
What is the Kiromic Biopharma dividend yield?
Kiromic Biopharma does not currently pay a dividend.
Does Kiromic Biopharma pay a dividend?
Kiromic Biopharma does not currently pay a dividend.
When does Kiromic Biopharma next pay dividends?
Kiromic Biopharma does not currently pay a dividend.
How do I buy Kiromic Biopharma shares?
To buy shares in Kiromic Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Kiromic Biopharma?
As of the previous close price of $2.51, shares in Kiromic Biopharma had a market capitalisation of $3.23m.
Where are Kiromic Biopharma shares listed?
Here are the trading details for Kiromic Biopharma:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: KRBP
What kind of share is Kiromic Biopharma?
Based on an overall assessment of its quality, value and momentum Kiromic Biopharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Kiromic Biopharma share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Kiromic Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kiromic Biopharma. Over the past six months, its share price has outperformed the S&P500 Index by +690.6%.
As of the last closing price of $2.51, shares in Kiromic Biopharma were trading +49.37% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Kiromic Biopharma PE Ratio?
The Kiromic Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.51.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Kiromic Biopharma?
We do not have data on Kiromic Biopharma's directors